The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Bi ...

The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below ... faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive ...

Blue Shield of California will offer Fresenius Kabi’s Humira biosimilar for $525 per month, compared to Humira’s $2,100 price. Most Blue Shield commercial members using the biosimilar will pay ...

As a result of the deal, Blue Shield of California will purchase a Humira biosimilar for $525 per monthly dose, significantly below the drug’s net price of $2,100. The biosimilar will be availab ...

CVS Caremark took Humira off its formularies in April. “With this latest update, we’re prepared to embrace the savings biosimilars offer and pave the way for access to the next wave of ...